Journal of Pediatric Gastroenterology & Nutrition:
Mechanisms of Lipotoxicity in NAFLD and Clinical Implications
Ibrahim, Samar H.*; Kohli, Rohit†; Gores, Gregory J.‡
*Division of Pediatric Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, MN
†Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
‡Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic.
Address correspondence and reprint requests to Gregory J. Gores, MD, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (e-mail: email@example.com).
Received 14 April, 2011
Accepted 20 May, 2011
This work was supported by NIH Grants DK41876 to G.J.G., DK084310-01 to R.K., the Mayo Foundation, and Cincinnati Children's Hospital Medical Center.
The authors report no conflicts of interest.
ABSTRACT: With the epidemic of childhood obesity, nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in pediatrics. NAFLD is strongly associated with insulin resistance and increased level of serum free fatty acids (FFAs). FFAs have direct hepatotoxicity through the induction of an endoplasmic reticulum stress response and subsequently activation of the mitochondrial pathway of cell death. FFAs may also result in lysosomal dysfunction and alter death receptor gene expression. Lipoapoptosis is a key pathogenic process in NAFLD, and correlates with progressive inflammation, and fibrosis. Accumulation of triglyceride in the liver results from uptake and esterification of FFAs by the hepatocyte, and is less likely to be hepatotoxic per se. To date, there are no proven effective therapies that halt NAFLD progression or unfortunately improve prognosis in children. The cellular mechanisms of lipotoxicity are complex but provide potential therapeutic targets for NAFLD. In this review we discuss several potential therapeutic opportunities in detail including inhibition of apoptosis, c-Jun-N-terminal kinase, and endoplasmic reticulum stress pathways.
Nonalcoholic fatty liver disease (NAFLD) has emerged as a growing public health problem linked to the increased incidence of childhood obesity. It is presently the most common cause of chronic liver disease in pediatrics. A population-based autopsy study reported that 13% of children and adolescents are affected with NAFLD; 23% of the subjects with NAFLD had evidence for steatohepatitis, whereas bridging fibrosis or cirrhosis was observed in 9% of children with nonalcoholic steatohepatitis (NASH). Overweight and obese children accounted for 81% of all of the cases of NAFLD (1). A cross-sectional study of liver biopsies, obtained during gastric bypass surgery performed in morbidly obese adolescents, also reported an increased prevalence of NAFLD in obese children; although 83% of the subjects had NAFLD, histopathological evidence of NASH was present in 20% of subjects, and portal inflammation and fibrosis were prevalent in some patients despite not meeting the diagnostic criteria for NASH (2). Long-term follow-up studies in adults with NASH suggest that the disease is usually slowly progressive but can ultimately lead to cirrhosis in a subset of patients (3–5) with its sequelae of portal hypertension, end-stage liver disease, hepatocellular carcinoma, and an increase in overall mortality (5,6). Many patients with “cryptogenic” cirrhosis occurring in adulthood have, in fact, had NASH since childhood (7).
The impact of NAFLD and its associated metabolic derangement during the active period of growth in childhood is substantial. In a series from Toronto, liver biopsies from pediatric patients with NAFLD displayed steatohepatitis in 88% and fibrosis in 71% of patients; a 10-year-old patient had already progressed to cirrhosis (8). Recent multicentric pediatric studies of patients with biopsy-proven NAFLD revealed the presence of fibrosis in 87% of subjects (9,10). Worsening of hepatic fibrosis was reported within a relatively short period in pediatric patients with NASH, raising concern for a more aggressive natural history of NASH in childhood (11). Children with NAFLD may develop end-stage liver disease with the consequent need for liver transplantation in adulthood. These children with serious liver disease may have a significantly shorter survival as compared with the general population (12). Thus, hepatolipotoxicity in children is a genuine public health concern.
In the context of the metabolic syndrome and obesity, insulin resistance plays an important role in the pathogenesis of NAFLD (13). Insulin resistance results in impaired suppression of lipolysis in adipose tissue and increased levels of circulating nonesterified or free fatty acids (FFAs) (14). FFAs are taken up by the liver, where they are esterified into neutral triglycerides (TGs); however, an excess of saturated FFAs overwhelms the capacity of the liver to esterify FFA, and induces lipotoxicity. Although the amount of fat in the liver is often considered as an index of disease severity, it is unlikely that the neutral TGs are lipotoxic. Rather, the magnitude of neutral TGs in the liver likely serves as a biomarker for the flux of FFAs delivered to the liver. This is in accordance with the finding that the majority of obese children with NAFLD have simple steatosis without features of NASH such as inflammation and/or fibrosis (2). Indeed, disease severity is directly proportional to the level of circulating FFAs (15).
Lipotoxicity is known to promote hepatocyte death, which in the context of NAFLD is termed lipoapoptosis (16,17). The severity of NAFLD correlates with the degree of hepatocyte lipoapoptosis (18) and is reflected by an increase of serum caspase–cleaved cytokeratin fragments (19). Recent studies have elucidated the cellular and molecular mechanisms of FFA-mediated liver injury in NASH; these studies are discussed in detail, together with potential mechanism-based therapeutic interventions for NASH.
HEPATIC LIPID METABOLISM IN NAFLD
Circulating FFAs derived from adipose tissue lipolysis play a critical role in the development of steatosis in NAFLD, contributing to 60% of hepatic fat content (20,21). De novo lipogenesis is the second most important mechanism, responsible for up to 30% of stored hepatic fat (20,22), whereas dietary lipid contributes only up to 10% of the hepatic lipid content (20). Decrease in the export of TGs in the form of very-low-density lipoproteins (VLDLs) and decreased oxidation of fatty acids, mainly at the level of the mitochondria, may play a role in selected cases with genetic susceptibility (23). FFA levels are increased in patients with NASH and correlate with disease severity (15). There is an increased body of evidence indicating that saturated FFAs are more hepatotoxic than unsaturated FFAs (24–26). In vitro studies indicate that the monounsaturated FFAs palmitoleate (PO) (a 16-carbon FFA with 1 carbon-carbon double bond, indicated C16:1) and oleate (C18:1) are less toxic than saturated FFAs such as palmitate (PA) (C16:0) and stearate (C18:0) (25–27). Moreover, PO was recently identified as an adipose tissue–derived lipid hormone (lipokine) that enhances muscle insulin sensitivity and suppresses hepatic steatosis (28). This difference in toxicity between saturated and unsaturated FFA is believed to be related to the ability of unsaturated FFA to more readily be esterified into neutral TGs than saturated FFAs (27,29,30). Thus, these data together suggest that hepatic esterification may be a detoxification process for FFA and not a toxic event itself.
Human observations further suggest that impaired cellular capacity to incorporate toxic FFAs into neutral TG may be a potential mechanism of liver injury in NASH (31). For example, total hepatic lipid content is greater in patients with simple steatosis when compared with patients with more advanced NAFLD, indicating that the presence of fat in the liver is either an innocent bystander or decreases as the disease progresses (32). A recent multicentric pediatric study exploring the relation between characteristics of hepatic steatosis and other histological features of NAFLD did not associate the severity of steatosis with any other histological feature of disease severity such as lobular inflammation, ballooning, or fibrosis (9). The lack of association between hepatic TG accumulation and insulin resistance has been demonstrated in human subjects with familial hypobetalipoproteinemia. Subjects with this disorder have high levels of hepatic TG because of their genetic defect in hepatic TG export. In these patients, hepatic and muscle insulin sensitivity was similar to controls matched for body mass index with normal hepatic TG levels (33).
Considerable experimental data in animals also suggest that saturated FFAs are hepatotoxic, whereas unsaturated FFAs are not injurious to the liver. In an experimental animal study in which leptin receptor–deficient mice (a genetic model of obesity and steatosis) were fed a methionine- and choline-deficient (MCD) diet, hepatic steatosis, apoptosis, reactive oxygen species (ROS) production, and fibrosis increased inversely to TG accumulation. Genetic deletion of diacylglycerol acyltransferase (DGAT)2, an enzyme responsible for intracellular FFA esterification, prevents cellular steatosis but accentuates FFA cytotoxicity through increased oxidative stress, hepatocellular apoptosis, and resultant fibrosis (34,35). Mice with hepatic overexpression of DGAT2 developed marked hepatic steatosis without liver injury or hepatic or systemic insulin resistance (35). Likewise, mice overexpressing DGAT1 in both macrophages and adipocytes were prone to obesity, but were protected against systemic inflammation and insulin resistance (36). In addition, genetic or pharmacological inhibition of stearoyl-coenzyme A (CoA) desaturase-1 (SCD1), the enzyme that converts saturated FFA into monounsaturated FFA, sensitizes hepatocytes to apoptosis induced by saturated FFA. SCD1 knockout mice fed an MCD diet accumulate less TG compared with wild-type mice, but have increased serum saturated FFA, hepatocellular apoptosis, and liver injury (30). In contrast, high-oleate MCD diet–fed animals have less severe apoptosis and liver injury in comparison with the animals fed a regular MCD diet, supporting the fact that monounsaturated fatty acids are preferentially incorporated into TG (30). Also, incorporation of palmitic acid into TG by cotreatment with oleic acid or by overexpression of SCD1 attenuates saturated FFA toxicity (29,34). Collectively, these data strongly implicate an increase in serum-saturated FFA as a hepatotoxic stimulus, while suggesting their esterification into TG as a detoxification process.
Fatty acids in the circulation cross the plasma membrane by diffusion or with the assistance of fatty acid transport proteins (FATP) (37) or fatty acid uptake transporters (eg, CD36) (38). Modification of the expression of these fatty acid transporters influences TG accumulation in the hepatocyte. FATP5 is exclusively expressed by hepatocytes and aids in the uptake of long-chain FFAs. FATP5 knockout animals are less likely to accumulate dietary lipid in the hepatocyte (39). Mice with liver-specific FATP2 knockdown have significantly reduced hepatic steatosis despite continued high-fat feeding, and improved fasting glucose, and insulin levels (40). Likewise, liver-fatty acid–binding protein (L-Fabp) (an abundant cytosolic lipid-binding protein expressed in mammalian hepatocytes) plays an important role in fat deposition in the liver. Indeed, genetic deletion of L-Fabp in mice results in decreased VLDL secretion and TG deposition in the liver (41). FATP5, CD36, and L-Fabp hepatic expression is increased in the livers of patients with early-stage NAFLD and correlates with liver fat content (42,43). These data emphasize the concept that hepatic TG accumulation is not caused by de novo hepatic lipogenesis, but rather FFAs flux to the liver.
PO as a Lipokine
A study by Cao et al (28) suggested PO as a lipokine (adipocyte-derived lipid hormones). They used quantitative lipidemic analyses in mice deficient in adipose tissue lipid chaperones. PO is virtually the only fatty acid derived from adipocytes that could significantly alter serum FFA composition. Also, PO has a low basal level that fluctuates rapidly under normal physiological conditions, reflecting de novo lipogenesis. In parallel with a variety of adipokines (eg, leptin, adiponectin), PO improves peripheral insulin resistance and suppresses hepatic steatosis, supporting its role as a systemic metabolic regulator. These animal data are observational, and the role of PO in human NASH requires further verification and study.
Role of Genes in Steatosis
There is an increased body of literature demonstrating the influence of genes in the development and severity of hepatic steatosis in NAFLD. The first genome-wide association study in NAFLD patients identified adiponutrin/patatin-like phospholipase domain–containing 3 gene (PNPLA3) as a key inherited determinant of liver TG accumulation. A single variant in PNPLA3 (rs738409 C/G) was strongly associated with hepatic fat content (44). A recent meta-analysis showed that PNPLA3 (rs738409) acts as a strong modifier of the natural history of NAFLD in different populations. NASH and higher-serum alanine transpeptidase (ALT) were more frequently observed in GG homozygous compared with CC homozygous. GG homozygous exerted a strong influence not only on liver fat accumulation but also on the susceptibility for a more aggressive disease (45). In pediatric patients, the high-risk PNPLA3 (rs738409) G allele is associated with an earlier presentation of disease (46). Moreover, the PNPLA3 (rs738409) G allele was shown to confer susceptibility to hepatic steatosis in obese youths without increasing the level of hepatic and peripheral insulin resistance (47). In addition to PNPLA3, a study revealed that single-nucleotide polymorphisms (SNPs) in the apolipoprotein C3 gene (APOC3), resulting in high expression of APOC3, is also an important mechanism related to increase susceptibility to TG accumulation and subsequently steatosis in NAFLD by impairing the clearance of diet-derived TG-rich particles (48).
Adipose Tissue as a Key Player in Hepatic Steatosis
There is an increased body of evidence suggesting that the interaction between peripheral tissues, mainly adipose tissue, and the liver play an important role in the development of NAFLD. During the development of obesity, expansion of adipose tissue results in activation of the death receptor and mitochondrial pathways of apoptosis in adipose tissue. Increase in adipocyte death results in the recruitment of macrophages to adipose tissue, with subsequent development of insulin resistance, and hepatic steatosis (23). Sabio et al (49) demonstrated that selective knockdown of adipose tissue c-Jun-N-terminal kinase (JNK)-1 in mice fed a high-fat diet was protective against the development of hepatic insulin resistance and steatosis. Adipose tissues of obese mice and humans display a proapoptotic phenotype as evidenced by a marked proapoptotic gene expression, such as Fas (a key death receptor belonging to the tumor necrosis factor [TNF] receptor family), and its specific ligand (FasL) (50). Several publications have linked Fas activation in adipose tissue to the metabolic dysregulation of obesity (50,51). Thus, blocking adipocyte apoptosis by inhibiting Fas-mediated pathways may be a potential therapeutic option for the treatment of obesity-associated metabolic complications including NAFLD.
Apoptosis or programmed cell death is a morphologic and pathogenic hallmark of NASH (18,52), which in the context of NAFLD, and secondary to its association with excess lipid deposition, is referred to as lipoapoptosis. In patients with NAFLD, the magnitude of hepatocyte apoptosis correlates with liver injury (18,52). For example, lipoapoptosis correlates with an aspartate aminotransferase/alanine aminotransferase ratio higher than 1 and hepatic fibrosis (18).
Apoptosis is regulated by members of the Bcl-2 protein family at the level of the mitochondria (53). These proteins can be classified into 3 categories: the guardians or antiapoptotic members of this family, which include Mcl-1, and Bcl-xL; the multidomain executioners or proapoptotic members of this family, which include Bax and Bak; and the messengers or biosensors of cell death, referred to as Bcl-2 homology 3 (BH3)–only proteins that include Bcl-2–interacting mediator of cell death (Bim) and p53-upregulated modulator of apoptosis (PUMA) (Fig. 1). Hepatocytes can undergo apoptosis via either an extrinsic or intrinsic pathway of cell death. The extrinsic pathway is activated by death ligands, Fas, and TNF-related apoptosis-inducing ligand (TRAIL). The intrinsic pathway is the apoptotic pathway activated by intracellular stress of membrane-bound organelles, such as ER, lysosomes, and mitochondria (54). In hepatocytes, both the intrinsic and extrinsic pathways converge onto the mitochondria, hence the critical role of Bcl-2 protein in hepatic injury.
Endoplasmic Reticulum Stress in Obesity
The endoplasmic reticulum (ER) is an intracellular membranous organelle that is responsible for many vital cellular functions including protein synthesis and for glycosylation, lipid synthesis, carbohydrate metabolism, calcium homeostasis, and drug detoxification. In conditions of ER stress, adaptive functions are activated by membrane sensors, which collectively initiate the unfolded protein response (55,56). The unfolded protein response serves to overcome the stress stimulus; however, with prolonged ER stress, apoptotic pathways are activated, causing cell demise (57). Biosensors of ER stress include protein kinase RNA-like ER kinase (PERK), inositol-requiring protein-1α (IRE-1α), and activating transcription factor 6 (ATF6). PERK dimerization drives the expression of the proapoptotic transcription factor C/EBP-homologous protein (CHOP) (58,59). IRE-1α activation leads to JNK activation and creates a spliced form of XBP-1 mRNA, which promotes degradation of misfolded ER glycoproteins (60,61). ATF6 optimizes protein folding during ER stress and ultimately facilitates recovery from acute stress (62). ATF6 also heterodimerizes with XBP1 and induces the ER-associated degradation components (63). ATF6 can also transcriptionally induce CHOP (57) (Fig. 2).
Ozcan et al (64) have shown that ER stress is increased in obesity. They investigated the expression of several markers of ER stress in dietary and genetic models of murine obesity. In these models, ER stress–induced JNK activation mediates insulin resistance through phosphorylation of insulin receptor substrate-1 (IRS-1). In a nutritional murine model of steatohepatitis, ER stress–induced XBP-1 mRNA splicing and CHOP expression correlate with the severity of apoptosis (65). In liver samples from patients with NAFLD, PERK is strongly activated. JNK activity is also increased, particularly in patients with NASH, and correlates with the degree of apoptosis (66). ER stress markers are elevated in the obese state when assessed on liver biopsies of patients undergoing bariatric surgery and decline following weight loss (67). Thus, ER stress appears to be a major injurious pathway in NAFLD.
There is increased evidence that the composition of fatty acids in the steatotic liver, rather than the steatosis, is the important factor in inducing ER stress. Mice with impaired ability to synthesize monounsaturated fatty acids because of a deletion of SCD1 exhibited marked induction of ER stress by enhanced splicing of XBP1, and increased expression of the stress-induced transcription factors CHOP in their livers (68). Rats fed a diet enriched with saturated fatty acids exhibited stronger activation of ER stress markers and liver injury in comparison with rats fed a normal or polyunsaturated fatty acid (PUFA)–enriched diet (65). Several in vitro studies demonstrate that ER stress is the mediator of saturated FFA-induced apoptosis (25–27). Unsaturated fatty acids do not induce ER stress or apoptosis, and co-incubation with monounsaturated fatty acid rescues hepatocytes from saturated FFA-induced ER stress and apoptosis (25–27). Saturated FFAs also contribute to ER stress through depleting ER-calcium stores in liver cells (26).
As discussed in greater detail later, ER stress–associated JNK and CHOP activation promotes apoptosis by enhancing expression and function of proapoptotic members of the Bcl-2 family, PUMA (69) and Bim (70,71). JNK activation stimulates formation of the transcription factor complex, activator protein (AP)-1 via phosphorylation of c-Jun. AP-1 facilitates PUMA expression by saturated FFA, in cooperation with the ER stress–related transcription factor CHOP (27). FFA-mediated BIM and PUMA induction result in activation of the multidomain proapoptotic member of Bcl-2 family Bax (24,69), causing mitochondrial dysfunction, activation of the caspase cascade, and subsequent cell death (72) (Fig. 3).
Controversies Regarding CHOP in NASH
CHOP is an inducible leucine zipper transcription factor that is present at low levels under normal conditions but is strongly expressed in response to ER stress (73). CHOP plays an important role in ER stress–induced apoptosis by activating both the intrinsic and the extrinsic pathways of apoptosis. Several in vitro studies have demonstrated CHOP induction in response to FFA-induced ER stress in liver cells (27,65), although the mechanism by which CHOP promotes apoptosis remains incompletely understood. CHOP was found to induce apoptosis in part through enhancing expression of TRAIL receptor 2 or death receptor 5 (DR5), a member of the TNF-receptor gene superfamily (74). Upregulation of DR5 promotes apoptosis by the extrinsic cellular pathway of cell death (75). FFAs upregulate DR5 expression in hepatocyte in vitro, and silencing DR5 expression protects against FFA-mediated apoptosis (unpublished observation). DR5 expression is also increased in human NASH (76) and animal models of NASH (77). In addition, CHOP-induced apoptosis involves the generation of ROS (57).
Despite all of the data implicating CHOP in ER stress–associated lipotoxicity, the role of CHOP in NAFLD remains complex. Genetic ablation of CHOP only reduces hepatocyte toxicity in vitro at high doses of FFA (27,78,79). More important, genetic deletion of CHOP does not reduce, and even accentuates, NAFLD in nutritional models of this disease in mice (78,79). The mechanism responsible for this paradoxical observation is unknown; however, perhaps CHOP deletion accentuates responses in cells other than hepatocyte (eg, Kupffer cells, adipose tissue macrophages), which aggravates liver injury. A hepatocyte conditional CHOP knockout will need to be developed to better understand and perhaps resolve this controversy.
C-Jun N-terminal Kinase-1
JNK belongs to a family of intracellular mitogen-activated protein (MAP) kinases; of 3 known JNK genes, JNK1 and JNK2 are expressed in the liver (80). JNK activation is pivotal in both the metabolic syndrome accompanying NAFLD and cellular apoptosis. JNK is activated in experimental murine dietary and genetic models of NASH (81–83) and also in human NASH (66,69). In mice models of genetic and dietary obesity ER stress–induced JNK activation phosphorylates IRS-1, suppressing insulin receptor signaling and inducing insulin resistance (64). Both JNK1 and JNK2 have been implicated in insulin resistance, although JNK1 is more strongly associated with steatohepatitis (82,83). In a mouse model of obesity, absence of JNK1 results in decreased adiposity and significant improvement of insulin sensitivity (81). Liver-specific knockdown of JNK1 in obese mice lowers blood glucose and insulin levels, but interestingly increases TG level (84). JNK1 but not JNK2 phosphorylates c-Jun, a member of the AP-1 transcription factor complex, which induces expression of the BH3-only protein PUMA (69,85). Genetic deletion of JNK1 prevents FFA-mediated c-Jun activation and PUMA induction by FFA (69).
JNK phosphorylates and activates the BH3-only proteins Bim and BAD and the proapoptotic Bcl-2 proteins Bax, which directly triggers the mitochondrial apoptotic pathway (24,85,86). Finally, it has been shown that JNK induces Fas and DR5 expression, sensitizing steatotic hepatocyte to circulating Fas or TRAIL-mediated toxicity (54,76). Thus, JNK activation appears to play a major role in the metabolic syndrome and lipotoxicity.
BH3-only Proapoptotic Proteins
Proapoptotic BH3-only proteins, especially Bim and PUMA, are key regulators of lipoapoptosis. Saturated FFA-treated hepatocytes have increased Bim and PUMA expression (69,70). Saturated FFAs induce protein phosphatase 2A (PP2A) activation by the transcription factor FoxO3a, a member of the forkhead box–containing proteins, class O. This transcription factor drives expression of the intracellular death mediator Bim (70). PP2A also increases Bim protein levels by rendering it refractory to proteasomal degradation (71). Interestingly, PP2A is known to be activated through ER stress (71,87). This observation links ER stress to Bim induction and potent apoptosis-inducing proteins.
PUMA induction is JNK1/AP-1–dependent (69). Genetic deletion of PUMA conveys resistance against PA-induced apoptosis in vitro. PUMA expression is increased in liver biopsies from patients with NASH when compared with patients with simple steatosis or controls (69). FFA-mediated Bim and PUMA induction result in activation of the multidomain proapoptotic member of the Bcl-2 family, Bax, initiating a mitochondrial pathway of cell death, with activation of caspase 3, 6, and 7, resulting ultimately in apoptosis (24,69). Moreover, Bax expression is also increased in a nutritional murine model of steatohepatitis (88), and structural and functional mitochondrial abnormality are observed in human NASH (10,14,18).
Antiapoptotic Bcl-2 Proteins
Mcl-1 is an antiapoptotic member of the Bcl-2 family. Saturated FFA induces a rapid degradation of Mcl-1 in hepatocytes by a proteasome-dependent pathway involving protein kinase C; inhibition of Mcl-1 degradation attenuates saturated FFA-induced apoptosis (89). Bcl-xL is another member of the antiapoptotic Bcl-2 family. Bcl-xL expression is reduced in a murine nutritional model of NASH (77). Overexpression of Bcl-xL blocks Bax-induced lysosomal permeabilization and attenuates saturated FFA induced-apoptosis in vitro (90). Furthermore, PUMA coimmunoprecipitates with Bcl-xL and Mcl-1, causing their inactivation, enhancing indirectly Bax activity (91).
Lysosomes are membrane-bound organelles with an acidic intravesicular pH. Lysosomes contain hydrolytic enzymes that are active at an acid to neutral pH. Cathepsin B is a cysteine protease whose endoproteolytic activity is maintained at neutral pH. Cathepsin B can be released into the cytosol with lysosomal permeabilization, where it mediates downstream mitochondrial permeabilization and caspase activation (92). Treatment of hepatocytes with FFA may activate the lysosomal pathway of apoptosis through Bax-induced lysosomal permeabilization, and release of cathepsin B into the cytosol. Cytosolic cathepsin B precipitates mitochondrial dysfunction and cell death (90,93). Likewise, release of cathepsin B into the cytoplasm is observed in human liver specimens with NAFLD and correlates with disease severity (93). In a dietary murine model of NAFLD, inactivation of cathepsin B protects against development of hepatic steatosis, liver injury, and insulin resistance (93). Furthermore, lysosomal permeabilization results in nuclear factor-κB (NF-κB) activation and TNF-α release; TNF-α in turn promotes lysosomal destabilization, leading to a feed-forward mechanism for lipotoxicity (93).
Ceramide is the main lipid in the metabolism of sphingolipids; ceramides have been recognized as an important factor in cell stress and death ligand–induced hepatocellular death (94,95), and also in insulin resistance and obesity (95,96). Ceramides are synthesized in the ER from sphingosine and a fatty acid moiety, usually palmitoyl CoA. Long-chain saturated FFA availability is the rate-limiting step in ceramide synthesis; therefore, obesity can be associated with excess ceramide synthesis. In addition, ceramide also can be rapidly generated from sphingomyelin by sphingomyelinase. The death ligands TNF-α and Fas can both activate sphingomyelinase, leading to rapid accumulation of ceramide (97,98). Thus, ceramide is a recognized intermediate linking both excess nutrients (ie, saturated FFA) and inflammatory cytokines (eg, TNF-α) to insulin resistance. Ceramides also play a role in insulin resistance by inhibiting insulin-induced glucose uptake (95). Despite the association of genes involved in ceramide signaling with liver fat content in patients with NAFLD (42), ER stress and apoptosis are independent of ceramide synthesis in an animal model of nutritional NASH (25). Moreover, PA-induced lysosomal permeabilization is ceramide independent (93), as is the induction of the proapoptotic Bcl-2 protein, Bim by FoxO3a (70). Although it is believed that ceramides may contribute to lipopaoptosis, perhaps via a Fas-induced signaling mechanism, liver ceramide content in patients with NAFLD is similar to normal controls (86). Thus, the potential role of ceramide in the pathogenesis of human NAFLD remains unclear and, for the most part, speculative.
Free cholesterol (FC) has been recognized as a hepatotoxic agent, whereas cholesterol esters are either stored in lipid droplets in macrophages or incorporated in apolipoprotein B–containing lipoproteins, such as chylomicrons in enterocytes and VLDL in hepatocytes (99). In an animal study designed to evaluate the role of dietary FC loading, rats fed a high-cholesterol diet developed microvesicular steatosis and were sensitized to the apoptotic effect of TNF-α. Sensitization to TNF-α was secondary to reduced mitochondrial glutathione stores; repletion of mitochondrial glutathione rescued FC-loaded liver from TNF-α-induced steatohepatitis (100). Although atherosclerotic macrophage-FC accumulation leads to calcium depletion and ER stress–induced apoptosis (101), FC loading of the ER in nutritional and genetic models of hepatic steatosis does not cause ER stress (100). A progressive increase in hepatic FC from controls with normal histology to subjects with simple steatosis and NASH has been reported, together with an increase of serum total cholesterol; in contrast to FC, liver cholesterol ester contents in subjects and controls were comparable (32). FC increases in human NASH and correlates with sterol regulatory element-binding protein-2 (SREBP-2) and steroidogenic acute regulatory protein (StAR) expression. SREBP-2, a transcription factor that plays an important role in cholesterol synthesis through hydroxymethylglutaryl-CoA (HMG-CoA) reductase, and StAR, a mitochondrial-cholesterol transporting polypeptide, were overexpressed in patients with NASH compared with those with simple steatosis (102). These findings suggest a role for mitochondrial FC in disease progression from steatosis to steatohepatitis, although the role of FC in FFA-induced ER stress in hepatocyte requires further investigation. We note that there is an association between atherosclerotic cardiovascular disease and NAFLD in adults. Animal models of atherosclerosis may also manifest NAFLD (103,104). Given the mechanistic link between cholesterol and atherosclerosis, the role for FC in NAFLD remains an important area of investigation.
POTENTIAL THERAPEUTIC INTERVENTIONS
Weight loss, thiazolidinedione, and antioxidants are the most extensively evaluated therapeutic options for NAFLD. According to a recent meta-analysis of randomized controlled trials for treatment of NAFLD, none can be considered markedly effective. Weight loss improves histological activity in NASH, but more than 50% of patients fail to achieve the target weight. Thiazolidinedione improves steatohepatitis markers, but leads to significant weight gain (105). In the PIVENS trial, vitamin E improved histological and serum biomarkers of liver injury in adult patients with NASH; however, fibrosis (the ultimate goal of hepatoprotective therapy) was not reduced, although the 2-year timeline of the study may not have been long enough to detect reversible fibrosis (106). The recently published treatment of NAFLD in children trial (TONIC) revealed that neither vitamin E nor metformin was effective in maintaining a sustained reduction in alanine transpeptidase level in pediatric patients with NAFLD; although the resolution of NASH was significantly greater in children treated with vitamin E, fibrosis was not improved (107). Clearly, there is unmet need for other therapies. Because apoptosis is a key pathogenic mechanism in NAFLD (18), several antiapoptotic agents may serve as potential therapeutic targets (Fig. 3).
If ER stress and protein misfolding are implicated in NAFLD pathogenesis, then it is likely that improvement of protein folding may serve as a therapeutic strategy in NAFLD (108). Chemical chaperones, such as glycerol and 4-phenyl butyric acid (PBA), represent a group of low-molecular-weight compounds that can stabilize protein conformation, improve ER folding capacity, and facilitate the appropriate trafficking of mutant proteins (108). PBA is an orally administered agent that was developed for the treatment of urea cycle disorders (109). It was also used in patients with homozygous β-thalassemia without problematic adverse effects (110). Bile acid derivatives, such as taurine-conjugated ursodeoxycholic acid (TUDCA), are effective in abolishing ER stress and preventing apoptosis by blocking calcium-mediated apoptotic pathway and caspase-12 activation (111). Treatment of obese and diabetic mice with PBA and TUDCA compounds alleviates ER stress resulting in normalization of blood glucose level, restoration of systemic insulin sensitivity, and resolution of fatty liver disease (112). Clinical trials in human NASH, however, did not show a benefit of ursodeoxycholic acid over placebo based on posttreatment histological criteria (79,105), although a study has shown that ursodeoxycholic acid is effective in improving hepatic and muscle insulin sensitivity in obese subjects (113). PBA has not been evaluated in human NASH.
Unsaturated FFAs attenuate saturated FFA-induced ER stress and cell death in liver cells (25–27,29). Unsaturated FFAs protect against lipotoxicity by reducing CHOP induction, JNK activation, and upregulation of the proapoptotic BH3-only proteins (PUMA and Bim) (27). Quantification of hepatic lipids by capillary gas chromatography showed a decrease in the levels of n-3 PUFA eicosapentaenoic and docosahexaenoic acids in patients with NASH (32); this deficiency may contribute to the progression of steatosis to steatohepatitis (114). In a small pilot trial of NAFLD patients receiving eicosapentaenoic acid, posttreatment liver biopsy showed improvement of hepatic steatosis, fibrosis, hepatocyte ballooning, and lobular inflammation (115). Larger-scale clinical trials are needed to confirm a potential therapeutic benefit of dietary supplementation with n-3 PUFAs in patients with NAFLD.
Caspase activation and apoptosis are key pathogenic features of NAFLD (18). In vitro studies have shown that the pan-caspase inhibitor Z-VAD-fmk is effective in attenuating saturated FFA-induced apoptosis (24,116). Also, the pan-caspase inhibitor VX-166 reduces progression to fibrosis in a mouse model of nutritional NASH; treatment with VX-166 decreases active caspase-3, TUNEL-positive cells, TG content, and fibrosis. However, ALT levels are similar in VX-166–treated mice and vehicle-treated controls (117). Although a phase 2 clinical trial was recently reported, accessing tolerability and efficacy of a new caspase inhibitor (GS9450) in adults with NASH (118), a longer trial was stopped because of drug toxicity. Other caspase inhibitors, however, should be tried in this disease.
Mitochondrial dysfunction is a key factor in the pathogenesis of NASH (14,119,120). Saturated FFAs induce mitochondrial dysfunction through Bax translocation to the lysosome, lysosomal disruption, and release of cathepsin B into the cytosol (93). This process was attenuated in vitro by either pharmacological cathepsin B inhibition (by cathepsin inhibitors CA07 and E-64) or genetic inhibition by shRNA technology (121). Likewise, in a dietary murine model of NAFLD, both genetic and pharmacological inactivation of cathepsin B preserved mitochondrial function, decreased oxidative stress, and protected against development of hepatic steatosis, liver injury, and insulin resistance (93,121). Thus, inhibition of cathepsin B activity may present another potential therapeutic target for treating NAFLD.
Glycogen synthase kinase (GSK) α and β are serine/threonine kinases (122,123). In an acute model of liver injury by acetaminophen, GSK-3β mediates JNK activation (124). In the context of saturated FFA-mediated lipoapotosis in vitro either pharmacological or genetic inhibition of GSK-3β attenuates apoptosis, through inhibition of JNK activation and subsequent PUMA induction (116). Further preclinical data are encouraged regarding a role of GSK inhibition in this disease. Such agents are being developed for cancer therapy and merit investigation in NASH.
JNK is a central mediator of the metabolic syndrome through its involvement in insulin resistance (82,83). It is also an important mediator of steatohepatitis (24,69), because JNK1 promotes liver injury in a murine model of steatohepatitis, whereas JNK2 inhibits hepatocyte cell death by blocking the mitochondrial death pathway (82,83). Although no selective JNK inhibitors are available, nonselective JNK inhibition pharmacologically by SP600125 decreased lipoapotosis in vitro (24,69,125) by attenuating saturated FFA-induced PUMA induction (69). The role of JNK in the metabolic syndrome is complex because it has effects in the hypothalamus, β cells of the pancreas, adipocytes, inflammatory cells, and liver. The role of JNK in obesity has been reviewed (126). Because the tissue distribution and target function of pharmacological inhibitors are not uniform, it is still likely that a JNK inhibitor with efficient hepatocyte uptake could be beneficial in decreasing lipoapoptosis and NASH.
Oxidative Stress and Antioxidants
Oxidative stress, caused by increased production of ROS and decreased antioxidant defense, is observed in human and experimental models of steatohepatitis (14,127,128). Yu et al (129) investigated the role of heme oxygenase-1, an antioxidant defense enzyme in nutritional steatohepatitis, and showed that heme oxygenase-1 can interrupt the progression of steatohepatitis by upregulating antioxidant chaperones, enzymes, and anti-inflammatory interleukin-22 and downregulating proinflammatory cytokines in vitro and in vivo. Induction of heme oxygenase with hemin, in a nutritional murine model of steatohepatitis, downregulates fibrosing genes, ameliorates fibrosing hepatitis (130), and suppresses hepatocyte apoptosis (131). In the PIVENS trial, vitamin E, a well-known antioxidant, induced histological improvement in adult patients with NASH, but did not reverse fibrosis during the 2-year period of the study (106). In a pediatric study, histological improvement of NASH provided by a combination of vitamins E and C, diet, and exercise was not superior to diet and exercise alone (132). The NASH Clinical Research Network recently completed the treatment of NAFLD in children (TONIC) randomized clinical trial using vitamin E and metformin, the results of which revealed that neither vitamin E nor metformin was superior to placebo in maintaining a sustained reduction in ALT during the 96-week period of the study. The resolution of NASH was significantly greater in children treated with vitamin E than with placebo; this was attributable mainly to significant improvement in hepatocellular ballooning by vitamin E treatment. Vitamin E treatment also significantly improved NAFLD activity score; however, vitamin E did not significantly affect steatosis, inflammation, or fibrosis. Patients treated with metformin also experienced significant reduction in ballooning, but there was no significant improvement in NAFLD activity score and NASH resolution compared with placebo (107). Clearly, the role of vitamin E as therapy for this disease requires further investigation.
NAFLD is the most common pediatric liver disease in developed countries. To date, no therapy has proven to be effective in reversing disease progression. NAFLD is associated with insulin resistance and increased levels of circulating FFA, which leads to deposition of fat mainly in the form of TG in the liver, causing steatosis. Excess FFA delivery to the liver exceeds the coping mechanisms of the liver and induces ER stress. ER stress activates numerous signaling pathways, including CHOP- and JNK-dependent upregulation of proapoptotic BH3-only proteins, leading to Bax activation, lysosomal permeabilization, mitochondrial dysfunction, caspase activation, and subsequent lipoapoptosis. Lipoapoptosis is a key player in the progression of steatosis into steatohepatitis. Understanding the molecular mechanism of lipotoxicity is of biomedical and public health importance for the development of new diagnostic markers and targeted therapies to halt disease progression.
1. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics
2. Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol
3. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology
4. Propst A, Judmaier G, Vogel W, et al. Prognosis in nonalcoholic steatohepatitis. Gastroenterology
5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology
6. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology
7. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA
8. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr
9. Carter-Kent C, Brunt EM, Yerian LM, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr
10. Carter-Kent C, Yerian LM, Brunt EM, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology
11. Kohli R, Boyd T, Lake K, et al. Rapid progression of NASH in childhood. J Pediatr Gastroenterol Nutr
12. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut
13. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol
2002; 17 (suppl):S186–S190.
14. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology
15. Nehra V, Angulo P, Buchman AL, et al. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci
16. Kusminski CM, Shetty S, Orci L, et al. Diabetes and apoptosis: lipotoxicity. Apoptosis
17. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology
18. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology
19. Feldstein AE, Wieckowska A, Feldstein AE, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology
20. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest
21. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest
22. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest
23. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis
24. Malhi H, Bronk SF, Werneburg H, et al. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem
25. Wei Y, Wang D, Topczewski F, et al. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab
26. Wei Y, Wang D, Gentile CL, et al. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol Cell Biochem
27. Akazawa Y, Cazanave S, Mott JL, et al. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol
28. Cao H, Gerhold K, Mayers JR, et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell
29. Listenberger LL, Han X, Lewis SE, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A
30. Li ZZ, Berk M, McIntyre TM, et al. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem
31. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta
32. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology
33. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology
34. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology
35. Monetti M, Levin MC, Watt MJ, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab
36. Koliwad SK, Streeper RS, Monetti M, et al. DGAT1-dependent triacylglycerol storage by macrophages protects mice from diet-induced insulin resistance and inflammation. J Clin Invest
37. Pohl J, Ring A, Hermann T, et al. Role of FATP in parenchymal cell fatty acid uptake. Biochim Biophys Acta
38. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology
39. Doege H, Baillie RA, Ortegon H, et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology
40. Falcon A, Doege H, Fluitt A, et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metabol
41. Newberry EP, Xie Y, Kennedy S, et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem
42. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol
43. Charlton M, Viker K, Krishnan A, et al. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology
44. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet
45. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148 M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology
46. Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology
47. Santoro N, Kursawe R, D’Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology
48. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med
49. Sabio G, Das M, Mora A, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science
50. Alkhouri N, Gornicka A, Berk MP, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem
51. Wueest S, Rapold RA, Schumann DM, et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest
52. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol
53. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol
54. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis
55. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol
56. Ji C, Kaplowitz N. ER stress: can the liver cope? J Hepatol
57. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol
58. Kaplowitz N, Than TA, Shinohara M, et al. Endoplasmic reticulum stress and liver injury. Semin Liver Dis
59. Rahman SM, Schroeder-Gloeckler JM, Janssen RC, et al. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology
60. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol
61. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest
62. Wu J, Rutkowski DT, Dubois M, et al. ATF6 alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev Cell
63. Yamamoto K, Sato T, Matsui T, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell
64. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science
65. Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology
66. Puri P, Mirshahi P, Cheung P, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology
67. Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes
68. Flowers MT, Keller MP, Choi Y, et al. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genom
69. Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem
70. Barreyro FJ, Kobayashi S, Bronk SF, et al. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem
71. Puthalakath H, O’Reilly LA, Gunn P, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell
72. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science
73. Wang XZ, Lawson Beth, Brewer JW, et al. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol Cell Biol
74. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem
75. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J
76. Malhi H, Barreyro FJ, Isomoto H, et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut
77. Farrell GC, Larter CZ, Hou JY, et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J Gastroenterol Hepatol
78. Soon RK Jr, Yan JS, Grenert JP, et al. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. Gastroenterology
79. Pfaffenbach KT, Gentile CL, Nivala AM, et al. Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death. Am J Physiol Endocrinol Metab
80. Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta
81. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature
82. Schattenberg JM, Singh R, Wang Y, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology
83. Singh R, Wang Y, Xiang Y, et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology
84. Yang R, Wilcox DM, Haasch DL, et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem
85. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem
86. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene
87. Christen V, Treves S, Duong FH, et al. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology
88. Wang Y, Ausman LM, Russell RM, et al. Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr
89. Masuoka HC, Mott J, Bronk SF, et al. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem
90. Feldstein AE, Werneburg NW, Li Z, et al. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol
91. Jabbour AM, Heraud JE, Daunt CP, et al. Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ
92. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene
93. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology
94. Mari M, Fernandez-Checa JC. Sphingolipid signalling and liver diseases. Liver Int
95. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res
96. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab
97. Morales A, Lee H, Goni FM, et al. Sphingolipids and cell death. Apoptosis
98. Paris F, Grassmé H, Cremesti A, et al. Natural ceramide reverses Fas resistance of acid sphingomyelinase(−/−) hepatocytes. J Biol Chem
99. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev
100. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab
101. Feng B, Pin MY, Li Y, et al. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol
102. Caballero F, Fernández A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol
103. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology
104. Wouters K, van Bilsen K, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett
105. Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology
106. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med
107. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA
108. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology
109. Maestri NE, Brusilow SW, Clissold DB, et al. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med
110. Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood
111. Xie Q, Khaoustov VI, Chung CC, et al. Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation. Hepatology
112. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science
113. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes
114. Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med
115. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol
116. Ibrahim SH, Akazawa Y, Cazanave SC, et al. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J Hepatol
117. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology
118. Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol
119. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol
120. Serviddio G, Sastre J, Bellanti F, et al. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med
121. Li Z, Berk M, McIntyre TM, et al. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology
122. Maurer U, Charvet C, Wagman AS, et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell
123. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci
124. Shinohara M, Ybanez MD, Win S, et al. Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem
125. Pagliassotti MJ, Wei Y, Wang D. Insulin protects liver cells from saturated fatty acid-induced apoptosis via inhibition of c-Jun NH2 terminal kinase activity. Endocrinology
126. Vallerie SN, Hotamisligil GS. The role of JNK proteins in metabolism. Sci Transl Med
127. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol
128. Kohli R, Pan X, Malladi P, et al. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem
129. Yu J, Chu ES, Wang R, et al. Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice. Gastroenterology
130. Wang RQ, Nan YM, Wu WJ, et al. Induction of heme oxygenase-1 protects against nutritional fibrosing steatohepatitis in mice. Lipids Health Dis
131. Nan Y, Wang R, Zhao S, et al. Heme oxygenase-1 prevents non-alcoholic steatohepatitis through suppressing hepatocyte apoptosis in mice. Lipids Health Dis
132. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology
This article has been cited 9 time(s).
Current Pharmaceutical Design
Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design, 19():
Current Pharmaceutical Design
Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design, 19():
European Journal of EndocrinologyNon-alcoholic fatty liver disease in common endocrine disordersEuropean Journal of Endocrinology
Life SciencesNonalcoholic fatty liver disease: Current and potential therapiesLife Sciences
Current Drug Metabolism
Recent Advances on Stearoyl-Coa Desaturase Regulation in Fatty Liver Diseases
Current Drug Metabolism, 13():
Journal of Hepatology
Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
Journal of Hepatology, 58(5):
Journal of Biological ChemistryMetabolomic Profiling Reveals a Role for Caspase-2 in LipoapoptosisJournal of Biological Chemistry
Mediators of InflammationLipotoxicity: Effects of Dietary Saturated and Transfatty AcidsMediators of Inflammation
Journal of Nutritional BiochemistryS-Allyl cysteine attenuates free fatty acid-induced lipogenesis in human HepG2 cells through activation of the AMP-activated protein kinase-dependent pathwayJournal of Nutritional Biochemistry
Bcl-2 homology 3-only protein; C/EBP-homologous protein (CHOP); c-Jun-N-terminal kinase; endoplasmic reticulum stress; free fatty acids; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis
Copyright 2011 by ESPGHAN and NASPGHAN
Highlight selected keywords in the article text.
Connect With Us
Visit JPGN.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.